Double-blind placebo-controlled comparison of the analgesic effects of single doses of lornoxicam and aspirin in patients with postoperative dental pain

Abstract

The pain experienced after third molar surgery was used as a model to evaluate the analgesic efficacy of a new non-steroidal anti-inflammatory drug, lornoxicam, in a Phase II study. One hundred and fifty fit, young adults participated in this randomised, single dose, double-blind, parallel group clinical study. Three doses of lornoxicam (2 mg, 4 mg, and 8 mg) were compared with aspirin 650 mg and placebo. Patients suffering from moderate to severe pain following surgery were monitored for up to 8 hours. All indices of efficacy showed similar results, all active treatments being associated with highly significant (P less than 0.0001) reductions in pain during the study period. Lornoxicam 8 mg demonstrated significant analgesic efficacy as compared with placebo. The two lower doses of lornoxicam and aspirin all showed apparent degrees of efficacy intermediate between that of placebo and lornoxicam 8 mg, although the trial proved to have inadequate power to show significant differences between these three treatments. Lornoxicam was very well tolerated at all three doses studied, with no adverse events definitely attributable to its administration.

Efficacy of ibuprofen versus lornoxicam after third molar surgery: a randomized, double-blind, crossover pilot study

“…According to the pertinent literature, the efficacy of lornoxicam has been shown for various surgical indications [9][10][11] as well as dental surgery [8,12,13]. Furthermore, it has been successfully used in the treatment of painful inflammatory musculoskeletal conditions [14].…”

Dose-related anti-inflammatory/analgesic effects of lornoxicam: A spinal c-Fos protein study in the rat

“…tended to give better pain relief than aspirin (a single dose of 650 mg p.o.) in patients after dental surgery [3].…”

“…Lornoxicam is a new compound combining the potency of the oxicams with a reduced risk of side effects. In comparison with other oxicams, lornoxicam has a relatively short elimination halflife (3 to 5 h [2]) and good gastrointestinal tolerability [3][4][5] which is an advantage in terms of less side effects than other oxicams. Like other NSAIDs, the anti-inflammatory/ analgesic activity of lornoxicam is related to the inhibitory action on prostaglandin synthesis, via inhibition of cyclooxygenase (COX) activity in the COX pathway of arachidonic acid metabolism [6].…”

“…The potent anti-inflammatory and analgesic activity of lornoxicam in both animal models [2] and clinical trials [3,5,9] has been reported. Clinical trials have demonstrated the analgesic effect of lornoxicam in patients with acute pain (acute sciatica/lumbosciatica and low back pain [10]) or chronic inflammatory pain (osteoarthritis, rheumatoid arthritis [4,5]), for review see [1].…”

Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other nsaids: A c-fos study in the rat

“…In comparison with other oxicams, lornoxicam has a relatively short elimination half-life (3-5 h [2]) and good gastrointestinal tolerability [3][4][5] which is an advantage in terms of fewer sideeffects than other oxicams. Potent anti-inflammatory and analgesic activities of lornoxicam in both animalmodels [2] and clinical trials [3][4][5][6][7] have been reported. In animal studies, lornoxicam had anti-inflammatory (carrageenan oedema) and analgesic (writhingtest) activity about 10 timesgreaterthan that oftenoxicam [2].…”